Data from randomized controlled trials demonstrate that Gla-300 has a lower hypoglycemia risk than intermediate-acting neutral protamine Hagedorn (NPH) insulin17,18 or the long-acting basal insulin analogs (Gla-100 and insulin detemir [IDet] 100 U/mL),19–24 with these findings being corroborated in real-world studies.25–29. The gene discussed is INS; the disease is Hypoglycemia.